MedTrace Logo

Diagnostic Role of Serum Testican and Ubiquitin Levels in Patients With Head Trauma

NCT06537713 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 89

Last updated 2024-08-05

No results posted yet for this study

Summary

We aimed to determine if testican-1 and ubiquitin can serve as early indicators for diagnosing worsening clinical course (presence of intraparenchymal pathology) and mortality in patients with moderate traumatic brain injury.

Conditions

  • Moderate Traumatic Brain Injury
  • Testican-1
  • Ubiquitin

Interventions

DIAGNOSTIC_TEST

Testican-1

Testican-1 and ubiquitin can serve as early indicators for diagnosing worsening clinical course and mortality in patients with moderate traumatic brain injury.

Sponsors & Collaborators

  • Kanuni Sultan Suleyman Training and Research Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-03-31
Completion
2021-04-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06537713 on ClinicalTrials.gov